Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Loading...
Embargo End Date
ICR Authors
Authors
Haanen, J
Ernstoff, M
Wang, Y
Menzies, A
Puzanov, I
Grivas, P
Larkin, J
Peters, S
Thompson, J
Obeid, M
Ernstoff, M
Wang, Y
Menzies, A
Puzanov, I
Grivas, P
Larkin, J
Peters, S
Thompson, J
Obeid, M
Document Type
Journal Article
Date
2020-01-01
Date Accepted
2020-04-24
Abstract
Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe toxicities again on rechallenge with checkpoint inhibitors. Consequently, medical oncologists and multidisciplinary teams are hesitant to retreat in this scenario, despite the fact that a number of patients may derive clinical benefit from this approach. Balancing such clinical benefit and treatment-related toxicities for each patient is becoming increasingly challenging as more and more patients with cancer are being treated with checkpoint inhibitors. In this manuscript, we provide an extensive overview of the relevant literature on retreatment after toxicity, and suggest prophylactic approaches to minimize the risk of severe irAE following rechallenge with immune checkpoint blockade, since treatment may be lifesaving in a number of occasions.
Citation
Journal for ImmunoTherapy of Cancer, 2020, 8 (1), pp. e000604 -
Source Title
Journal for ImmunoTherapy of Cancer
Publisher
BMJ PUBLISHING GROUP
ISSN
2051-1426
eISSN
2051-1426
2051-1426
2051-1426